Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C, CA184-043, Investigators

Open source

DOI: 10.1016/j.eururo.2020.07.032
Published: 2020 Dec
Container: European urology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eururo.2020.07.032,
  title = {Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.},
  author = {Fizazi K and Drake CG and Beer TM and Kwon ED and Scher HI and Gerritsen WR and Bossi A and den Eertwegh AJMV and Krainer M and Houede N and Santos R and Mahammedi H and Ng S and Danielli R and Franke FA and Sundar S and Agarwal N and Bergman AM and Ciuleanu TE and Korbenfeld E and Sengeløv L and Hansen S and McHenry MB and Chen A and Logothetis C and CA184-043, Investigators},
  year = {2020},
  journal = {European urology},
  doi = {10.1016/j.eururo.2020.07.032},
  url = {https://doi.org/10.1016/j.eururo.2020.07.032}
}

RIS

TY  - JOUR
TI  - Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
AU  - Fizazi K
AU  - Drake CG
AU  - Beer TM
AU  - Kwon ED
AU  - Scher HI
AU  - Gerritsen WR
AU  - Bossi A
AU  - den Eertwegh AJMV
AU  - Krainer M
AU  - Houede N
AU  - Santos R
AU  - Mahammedi H
AU  - Ng S
AU  - Danielli R
AU  - Franke FA
AU  - Sundar S
AU  - Agarwal N
AU  - Bergman AM
AU  - Ciuleanu TE
AU  - Korbenfeld E
AU  - Sengeløv L
AU  - Hansen S
AU  - McHenry MB
AU  - Chen A
AU  - Logothetis C
AU  - CA184-043, Investigators
PY  - 2020
JO  - European urology
DO  - 10.1016/j.eururo.2020.07.032
UR  - https://doi.org/10.1016/j.eururo.2020.07.032
ER  -

APA

K, F., CG, D., TM, B., ED, K., HI, S., WR, G., A, B., AJMV, D. E., M, K., N, H., R, S., H, M., S, N., R, D., FA, F., S, S., N, A., AM, B., TE, C., E, K., L, S., S, H., MB, M., A, C., C, L., & Investigators, C. (2020). Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.. European urology. https://doi.org/10.1016/j.eururo.2020.07.032

Source records

pubmed · retrieved 2026-09-25T13:25:51.626Z